All In Biotech

Drug Trial Radar · NCT00108004

Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus

A Phase 3B, Multicenter, Open-Label Study Investigating the Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus Who Have Not Achieved Glycemic Targets With Insulin Therapy

Last checked: Nov 20, 2026Latest source record: May 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Planned (sponsor's estimate)

Start

Apr 2003

Primary completion

Jun 2005

Study completion Jun 2005

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label, multicenter study is designed to investigate the clinical utility and safety of pramlintide treatment in subjects with type 1 and type 2 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.

Conditions

  • Type 1 Diabetes Mellitus
  • Type 2 Diabetes Mellitus

Interventions

  • pramlintide acetateDrug

    Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate the clinical utility and safety of pramlintide in subjects with type 1 and type 2 diabetes mellitusTime frame: 6 months
  2. Understand management issues in subjects with type 1 and type 2 diabetes mellitusTime frame: 6 months

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Anaheim, California

  • Research Site

    Escondido, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Gatos, California

  • Research Site

    San Francisco, California

  • Research Site

    Torrance, California

  • Research Site

    New Britain, Connecticut

  • Research Site

    Norwalk, Connecticut

  • Research Site

    Norwich, Connecticut

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Clearwater, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Columbus, Georgia

  • Research Site

    Honolulu, Hawaii

  • Research Site

    Idaho Falls, Idaho

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Vincennes, Indiana

  • Research Site

    Topeka, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Lexington, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Bloomfield Hills, Michigan

  • Research Site

    Tupelo, Mississippi

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Reno, Nevada

  • Research Site

    Moorestown, New Jersey

  • Research Site

    Neptune City, New Jersey

  • Research Site

    Roseland, New Jersey

  • Research Site

    New York, New York

  • Research Site

    Williston Park, New York

  • Research Site

    Yonkers, New York

  • Research Site

    Greenville, North Carolina

  • Research Site

    Lakewood, Ohio

  • Research Site

    Westlake, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Wilkes-Barre, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Sumter, South Carolina

  • Research Site

    Chattanooga, Tennessee

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.